The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's...

The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's...


Crispr Therapeutics AG and Vertex Pharmaceuticals Incorporated said the FDA has lifted the clinical hold and accepted the investigational new drug application, or IND, for CTX001, their gene-edited hematopoietic stem-cell therapy for treating sickle cell disease, or SCD. The companies said they have already obtained approvals of Clinical Trial Applications for CTX001 in multiple countries outside the U.S. for both beta-thalassemia and SCD.



from Biotech News